3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
14
Recruiting
7
Terminated
5
Active not recruiting
5
Unknown
4
Withdrawn
2
Not yet recruiting
2
Enrolling by invitation
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
8
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
HER2-positive Breast Cancer
1
Exanthema
1
Diarrhea
1
Brest Cancer
1
Breast Diseases
1
Breast Cancer Metastatic
1
Advanced/Metastatic Solid Tumors
1
Advanced Breast Cancer
1
Interventions
trastuzumab deruxtecan
4
Cyclophosphamide
4
pembrolizumab
3
fludarabine
3
Standard of Care
3
Cisplatin
3
Bevacizumab
3
toripalimab
2
sacituzumab govitecan
2
fludarabine phosphate
2
Specimen Handling
2
Radiosurgery
2
Pemetrexed
2
Palliative Care
2
Nivolumab
2
Injections
2
Gemcitabine
2
Fulvestrant
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
vedolizumab
1
tislelizumab
1
sintilimab
1
lobaplatin
1
lenvatinib
1
ivosidenib
1
irinotecan sucrosofate
1
exemestane
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasm Metastasis
×
Fulvestrant
×
Clear all
NCT07340619
2026-05-19
EPIBREAST
UNICANCER
Phase 2
Not yet recruiting
51 enrolled
NCT07163481
2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1
Not yet recruiting
12 enrolled